Nervous Disorder TRIZ Cases

A recombinant AAV vector uses a mutant constitutive promoter to deliver GAA coding sequences for treating Pompe disease.

Peptide-oligourea foldamers incorporate urea residues to stabilize secondary structures, resisting enzymatic degradation while maintaining receptor binding.

A multidrug infusion formulation combines opioid, Na channel blocker, and alpha2-receptor agonist components.

SerpinF2-binding molecules inhibit hemorrhage and edema caused by tissue plasminogen activator toxicity in ischemic stroke treatment.

Ammonia converts organic solvents to water-soluble forms, hardening emulsion droplets into drug-loaded polymeric microspheres without toxic residue.

Granule nesting synchronizes enhancer and active ingredient release, resolving unsynchronized delivery bottlenecks.

Engineered anti-PACAP antibodies with optimized complementarity determining regions bind neuropeptides to treat headache and migraine pain.

Formula I compounds inhibit RORγ activity, addressing the limited availability of effective modulators for treating multiple sclerosis and rheumatoid arthritis.

Modified Fc polypeptides enable TREM2 antibodies to bind transferrin receptors and cross the blood-brain barrier.

Anti-Sortilin antibodies block lysosomal clearance via the E-region, resolving progranulin deficiency in frontotemporal dementia.

Merging sequential operations into a single extraction cycle reduces processing time and energy consumption while maintaining product purity.

Measuring IGFBP2 concentration replaces tumor size tracking to reduce time required for therapeutic adjustments.

Intracisternal magna injection of M-CSF stimulates perivascular macrophages, clearing debris accumulation while maintaining brain perfusion.

A Yukgunjatang herbal composition improves memory and cognitive function through synergistic neuroprotective effects.

A pharmaceutical composition containing the tripeptide glutamyl-aspartyl-glycine regulates biogenic amine levels in the brain and blood.

Cyclosporin quinolinium conjugates deliver neuroprotective agents to mitochondria via electrostatic interactions.

Small-molecule signaling pathway inhibitors enable long-term ectodermal cell culture and mass production without genetic modification.

Deacylated saponins stimulate Th2 immunity without triggering harmful inflammatory responses.

Combining bupropion with dextromethorphan inhibits CYP2D6 enzyme activity, resolving low plasma levels caused by rapid metabolism in extensive metabolizers.

A topical pharmaceutical composition combines a hydration agent with an anesthetic to reduce scar size and symptoms.

TSTA-3 and RASGRP2 peptides induce antigen-specific tolerance by targeting liver and spleen.

Purified cannabidiol addresses treatment-resistant epilepsy by significantly reducing seizure frequency where standard anti-epileptic drugs fail.

Adeno-associated viral vectors increase FMRP expression to reduce DYRK1A and APP levels in Fragile X syndrome treatment.

Allosteric antagonists bind beta-1 integrin distinct sites to shift affinity states, reversing tissue injury damage and cell death.

Aminopyridines block potassium channels to restore impaired motor function in cerebral palsy patients.

Salt formation reduces hygroscopicity in histone deacetylase inhibitors, ensuring storage stability and reproducibility for industrial manufacturing.

Microneedle arrays create aqueous pores to bypass first-pass metabolism and improve cannabinoid bioavailability.

Optimizing pH to 5.5 reduces viscosity and aggregation, enabling stable subcutaneous injection.

Combines THC and CBD ratios with alkylating agents to reduce tumor volume while limiting toxicity to normal brain tissue.

Human facilitating cells mediate hematopoietic stem cell engraftment while reducing graft-versus-host disease risk.

A nested sandwich immunoassay kit captures Aβ40 and Aβ42 peptides using specific monoclonal antibodies to enable precise quantification.

Halving the rosuvastatin dose prevents increased plasma concentration caused by teriflunomide transporter inhibition.

Engineered antibodies bind amyloid-beta protofibrils with high specificity to enable targeted detection and therapeutic clearance.

LRP-1 ligand decorated polymersomes drive receptor transcytosis to clear amyloid-beta and tau proteins from the brain.

A herbal composition combining specific plant extracts and minerals to treat addiction.

Engineered chondroitinase ABCI mutants resist UV and heat inactivation while degrading glial scar proteoglycans to restore motor function.

Base editing replaces nuclease cleavage with cytosine deamination to create precise PCSK9 mutations, reducing off-target effects and genomic instability.

Dual agonist hybrid peptides reduce appetite and enhance energy metabolism while minimizing adverse side effects associated with single-target therapies.

Compounds modulate NMDA receptor activity via the glycine binding site, balancing potency and therapeutic index for oral delivery.

Formula I heteroaryl compounds optimize potency and pharmacokinetic profiles to address insufficient small molecule therapies for Huntington's disease.

Macrocyclic tetrapeptides antagonize kappa opioid receptors with high selectivity, reducing side effects while maintaining analgesic efficacy.

Modulating gut microbiome indoles reduces indoxyl sulfate and increases indole-3-propionic acid to alleviate depression symptoms.

Cycloundecadepsipeptides resolve the trade-off between binding affinity and aqueous solubility while eliminating adverse immunosuppression.

Anti-MS4A4A antibodies increase soluble TREM2 levels and reduce M2 markers, addressing limited therapeutic options for neurodegenerative diseases.

An anti-CD3 antibody modulates microglial inflammatory phenotypes to treat neurological disorders.

Replacing human serum albumin with amino acids and antioxidants maintains biological activity while eliminating viral transmission risks.